Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 1471: Which antibiotic resistance mechanism involves the modification of drug targets within bacterial cells?

A. Drug efflux
B. Drug inactivation
C. Target modification (Correct Answer)
D. Decreased permeability

Explanation: ***Target modification*** - **Target modification** involves altering the **bacterial structures** that antibiotics normally bind to, thereby preventing the drug from exerting its effect. - This mechanism often arises from **mutations** in genes encoding the target proteins (e.g., altered ribosomal proteins for aminoglycosides, modified penicillin-binding proteins for beta-lactams). *Drug efflux* - **Drug efflux** involves **pump proteins** that actively transport antimicrobial drugs out of the bacterial cell, reducing their intracellular concentration below therapeutic levels. - This mechanism does not alter the drug's target but rather prevents the drug from reaching it effectively. *Drug inactivation* - **Drug inactivation** involves bacterial enzymes that chemically modify or degrade the antibiotic, rendering it ineffective. - A classic example is **beta-lactamase** enzymes that hydrolyze the beta-lactam ring of penicillins and cephalosporins. *Decreased permeability* - **Decreased permeability** occurs when bacteria alter their **outer membrane porins** or other transport systems, limiting the entry of antibiotics into the cell. - This mechanism reduces the amount of drug that reaches its target but does not modify the target itself.

Question 1472: A patient presents with multidrug-resistant tuberculosis. Which drug, acting as an ATP synthase inhibitor, would be the most appropriate for treatment?

A. Rifampin
B. Isoniazid
C. Bedaquiline (Correct Answer)
D. Ethambutol

Explanation: ***Bedaquiline*** - Bedaquiline is a diarylquinoline antimycobacterial agent that specifically inhibits **mycobacterial ATP synthase**, a crucial enzyme for energy production in *M. tuberculosis*. - It is a **novel drug approved for multidrug-resistant tuberculosis (MDR-TB)** due to its unique mechanism of action and efficacy against resistant strains. *Rifampin* - Rifampin inhibits **DNA-dependent RNA polymerase**, preventing bacterial RNA synthesis. - While a first-line agent, resistance to rifampin is a defining characteristic of **MDR-TB**, making it inappropriate for this specific scenario. *Isoniazid* - Isoniazid is a **prodrug** that inhibits the synthesis of **mycolic acid**, an essential component of the mycobacterial cell wall. - Resistance to isoniazid is also a key component of **MDR-TB**, rendering it ineffective for this patient. *Ethambutol* - Ethambutol inhibits **arabinosyl transferase**, an enzyme involved in the synthesis of the mycobacterial **cell wall**. - Although it is part of the first-line regimen, it is not an ATP synthase inhibitor, and resistance can develop, which would not address the MDR nature of the infection.

Question 1473: Which drug class is known for inhibiting DNA replication in herpes viruses and providing effective antiviral therapy?

A. Protease inhibitors
B. Integrase inhibitors
C. Fusion inhibitors
D. Nucleoside analogs (Correct Answer)

Explanation: ***Nucleoside analogs*** - These drugs, such as **acyclovir** and **ganciclovir**, mimic natural nucleosides and are incorporated into the viral DNA upon replication by viral polymerase. - This incorporation leads to **chain termination** and inhibition of viral DNA synthesis, effectively stopping herpes virus proliferation. *Protease inhibitors* - These drugs **block the activity of viral proteases**, enzymes essential for cleaving viral polyproteins into functional proteins needed for virus assembly. - They are primarily used in the treatment of **HIV** and **hepatitis C virus** infections, not herpes viruses. *Integrase inhibitors* - These agents interfere with the action of **viral integrase**, an enzyme crucial for inserting the viral DNA into the host cell's genome. - They are a class of **antiretroviral drugs** specifically used in the treatment of **HIV infection**. *Fusion inhibitors* - These drugs **prevent the fusion of the viral envelope with the host cell membrane**, thereby blocking viral entry into the cell. - They are used in the treatment of **HIV** (e.g., enfuvirtide) and **respiratory syncytial virus (RSV)**, but not herpes viruses.

Question 1474: What is the mechanism of action of penicillin?

A. Inhibits protein synthesis
B. Disrupts cell membrane
C. Inhibits cell wall synthesis (Correct Answer)
D. Inactivates nucleic acids

Explanation: ***Inhibits cell wall synthesis*** - Penicillin belongs to the **beta-lactam** class of antibiotics, which primarily interfere with the synthesis of the bacterial **peptidoglycan cell wall** [1], [2]. - This mechanism weakens the cell wall, leading to **osmotic lysis** and bacterial death, making it a **bactericidal** agent [2]. *Inhibits protein synthesis* - This mechanism is characteristic of antibiotics like **aminoglycosides** (e.g., gentamicin) and **tetracyclines** (e.g., doxycycline) which bind to bacterial ribosomes. - Penicillin does not target the bacterial protein synthesis machinery. *Disrupts cell membrane* - Antibiotics that disrupt the cell membrane, such as **polymyxins**, increase membrane permeability causing leakage of intracellular contents. - Penicillin does not directly act on the bacterial cell membrane; its action is primarily on the cell wall outside the membrane [1]. *Inactivates nucleic acids* - Antibiotics like **quinolones** (e.g., ciprofloxacin) inhibit DNA gyrase, while **rifamycins** (e.g., rifampin) inhibit RNA polymerase, thereby inactivating nucleic acid synthesis. - Penicillin's mechanism of action does not involve direct inactivation of bacterial DNA or RNA.

Question 1475: Which class of antibiotics acts by inhibiting bacterial cell wall synthesis and is effective against Gram-positive bacteria?

A. Macrolides
B. Quinolones
C. Penicillins (Correct Answer)
D. Aminoglycosides

Explanation: ***Penicillins*** - **Penicillins** belong to the **beta-lactam** class of antibiotics, which work by inhibiting the synthesis of the bacterial cell wall. - They are particularly effective against many **Gram-positive bacteria** due to the structure of these bacteria's cell walls. *Macrolides* - **Macrolides** inhibit bacterial protein synthesis by binding to the **50S ribosomal subunit**. - They do not target the cell wall and have a broader spectrum, including some atypical bacteria. *Quinolones* - **Quinolones** (e.g., ciprofloxacin) inhibit bacterial **DNA gyrase** and **topoisomerase IV**, enzymes essential for DNA replication. - They are entirely distinct from cell wall synthesis inhibitors. *Aminoglycosides* - **Aminoglycosides** (e.g., gentamicin) inhibit bacterial protein synthesis by binding to the **30S ribosomal subunit**. - Their mechanism of action is unrelated to the bacterial cell wall.

Question 1476: What is the primary mechanism of action of the antifungal drug amphotericin B?

A. Inhibition of cell wall synthesis
B. Inhibition of nucleic acid synthesis
C. Binding to ergosterol in fungal cell membranes (Correct Answer)
D. Inhibition of protein synthesis

Explanation: ***Binding to ergosterol in fungal cell membranes*** - **Amphotericin B** is a **polyene antifungal** that binds specifically to **ergosterol**, a sterol found in fungal cell membranes. - This binding creates **pores** and **channels** in the membrane, leading to increased permeability, leakage of intracellular components, and ultimately **fungal cell death**. *Inhibition of cell wall synthesis* - This mechanism is characteristic of antifungal drugs like **echinocandins** (e.g., caspofungin), which target **β-(1,3)-D-glucan synthesis**. - Amphotericin B does not affect the fungal cell wall, but rather acts on the cell membrane. *Inhibition of nucleic acid synthesis* - This mechanism is primarily associated with antifungals like **flucytosine**, which is converted into a cytotoxic metabolite that interferes with DNA and RNA synthesis. - Amphotericin B does not directly inhibit the synthesis of genetic material. *Inhibition of protein synthesis* - While some **antibiotics** (e.g., tetracyclines, aminoglycosides) target bacterial protein synthesis, this is not a primary mechanism of action for antifungal drugs. - Antifungals generally act on unique fungal structures or metabolic pathways.

Question 1477: A patient with peptic ulcers is treated with a combination therapy that includes clarithromycin. What is the purpose of this antibiotic in the treatment regimen?

A. Reduce acid production
B. Neutralize stomach acid
C. Eradicate Helicobacter pylori (Correct Answer)
D. Promote mucosal healing

Explanation: ***Eradicate Helicobacter pylori***- **Clarithromycin** is a macrolide antibiotic and a key component of **H. pylori eradication regimens** [1].- It targets the bacteria directly to resolve the underlying infection causing peptic ulcers [1].- Successful eradication significantly reduces ulcer recurrence rates [1].- Used in combination with a **PPI** and another antibiotic (amoxicillin or metronidazole) [1, 2].*Reduce acid production*- Clarithromycin is an antibiotic with no effect on acid secretion- **Proton pump inhibitors (PPIs)** serve this role in combination therapy*Neutralize stomach acid*- This is the function of **antacids**, not antibiotics- Clarithromycin's action is antimicrobial, not acid-neutralizing*Promote mucosal healing*- While H. pylori eradication indirectly promotes healing [1], clarithromycin does not directly stimulate mucosal repair- **Acid suppression via PPIs** allows the gastric and duodenal mucosa to heal

Question 1478: Which antifungal agent is considered the most effective for treating invasive mucormycosis in immunocompromised patients?

A. Amphotericin B (Correct Answer)
B. Voriconazole
C. Fluconazole
D. Itraconazole

Explanation: ***Amphotericin B*** - **Amphotericin B**, particularly its lipid formulations, is considered the **first-line and most effective antifungal agent** for the treatment of invasive mucormycosis due to its broad spectrum of activity against Mucorales. - It works by binding to **ergosterol** in the fungal cell membrane, leading to pore formation and cell death, which is critical for rapidly progressive infections like mucormycosis. *Voriconazole* - **Voriconazole** is highly effective against *Aspergillus* and *Candida* species but has **minimal or no activity** against the **Mucorales** fungi that cause mucormycosis. - Using voriconazole for mucormycosis could lead to treatment failure and progression of the disease due to its **lack of efficacy** against this specific fungal group. *Fluconazole* - **Fluconazole** is a narrow-spectrum azole primarily used for *Candida* infections, particularly *Candida albicans*, and has **no activity** against **Mucorales** species. - Therefore, it is completely **ineffective** for treating invasive mucormycosis and should not be used. *Itraconazole* - While **itraconazole** has a broader spectrum than fluconazole and some activity against certain molds, it has **limited or unreliable activity** against **Mucorales** and is not recommended for invasive mucormycosis. - Its **pharmacokinetic profile** and drug interactions also make it less suitable as a primary agent for severe, life-threatening infections like mucormycosis compared to amphotericin B.

Question 1479: A patient with a history of genital herpes presents with a new cluster of vesicles on the labia. Which medication is the most appropriate for the treatment of this condition?

A. Acyclovir
B. Valacyclovir (Correct Answer)
C. Famciclovir
D. Ganciclovir

Explanation: ***Valacyclovir*** - It is a **prodrug of acyclovir** with improved oral bioavailability (54% vs 15-20%), allowing for less frequent dosing (typically twice daily) and better patient adherence. - **Valacyclovir** is highly effective in treating recurrent **genital herpes infections**, reducing the duration and severity of outbreaks by 1-2 days when started early. - **Most convenient dosing regimen** for suppressive therapy (500 mg once daily) makes it a preferred choice in clinical practice. *Incorrect: Acyclovir* - While effective for **genital herpes** and the original drug for HSV treatment, it has lower oral bioavailability (15-20%) compared to valacyclovir. - Requires **more frequent dosing** (200 mg five times daily or 400 mg three times daily for acute outbreaks), which can lead to reduced patient adherence. - Still an acceptable alternative, especially where cost is a consideration. *Incorrect: Famciclovir* - Famciclovir is a **prodrug of penciclovir** and is also effective for HSV infections with good bioavailability (77%). - Dosing is typically **250 mg three times daily** for acute outbreaks or 250 mg twice daily for suppression. - Clinically equivalent efficacy to valacyclovir, but slightly less convenient dosing schedule makes valacyclovir marginally preferred. *Incorrect: Ganciclovir* - Ganciclovir is primarily indicated for **cytomegalovirus (CMV) infections**, particularly in immunocompromised patients. - **Not recommended as first-line therapy** for HSV infections due to significant toxicity (bone marrow suppression) and the availability of safer, more effective alternatives. - Reserved for severe, acyclovir-resistant HSV cases in immunocompromised patients.

Question 1480: Which of the following antibiotics is classified as a macrolide and is used for respiratory tract infections due to its effective activity against atypical bacteria?

A. Ceftriaxone
B. Ciprofloxacin
C. Azithromycin (Correct Answer)
D. Vancomycin

Explanation: ***Azithromycin*** - Azithromycin is a **macrolide antibiotic** known for its excellent activity against **atypical bacteria** such as *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, and *Legionella pneumophila*, which are common causes of respiratory tract infections. - Its **long half-life** allows for once-daily dosing and shorter courses of therapy, making it a preferred choice for community-acquired pneumonia and other respiratory infections. *Ceftriaxone* - Ceftriaxone is a **third-generation cephalosporin antibiotic**, not a macrolide, primarily targeting **gram-positive** and **gram-negative bacteria**. - While effective against many respiratory pathogens, it has **limited activity against atypical bacteria**, unlike macrolides. *Ciprofloxacin* - Ciprofloxacin is a **fluoroquinolone antibiotic**, not a macrolide, with a broad spectrum of activity against **gram-negative bacteria** and some **atypical bacteria**. - While effective for some respiratory infections, its mechanism of action and classification differ significantly from macrolides. *Vancomycin* - Vancomycin is a **glycopeptide antibiotic** primarily used for **serious gram-positive infections**, particularly those caused by **methicillin-resistant *Staphylococcus aureus* (MRSA)**. - It is **not effective against atypical bacteria** and is generally reserved for more severe or resistant infections, not typically first-line for common respiratory tract infections.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free